Edwards Lifesciences (EW) Revenue & Revenue Breakdown
Edwards Lifesciences Revenue Highlights
Latest Revenue (Y)
$6.00B
Latest Revenue (Q)
$1.39B
Main Segment (Y)
Transcatheter Aortic Valve Replacement
Main Geography (Y)
UNITED STATES
Edwards Lifesciences Revenue by Period
Edwards Lifesciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $6.00B | 11.56% |
| 2022-12-31 | $5.38B | 2.86% |
| 2021-12-31 | $5.23B | 19.29% |
| 2020-12-31 | $4.39B | 0.88% |
| 2019-12-31 | $4.35B | 16.79% |
| 2018-12-31 | $3.72B | 8.37% |
| 2017-12-31 | $3.44B | 15.91% |
| 2016-12-31 | $2.96B | 18.85% |
| 2015-12-31 | $2.49B | 7.35% |
| 2014-12-31 | $2.32B | 13.56% |
| 2013-12-31 | $2.05B | 7.68% |
| 2012-12-31 | $1.90B | 13.17% |
| 2011-12-31 | $1.68B | 16.01% |
| 2010-12-31 | $1.45B | 9.51% |
| 2009-12-31 | $1.32B | 6.76% |
| 2008-12-31 | $1.24B | 13.44% |
| 2007-12-31 | $1.09B | 5.22% |
| 2006-12-31 | $1.04B | 3.92% |
| 2005-12-31 | $997.90M | 7.13% |
| 2004-12-31 | $931.50M | 8.25% |
| 2003-12-31 | $860.50M | 22.23% |
| 2002-12-31 | $704.00M | 1.73% |
| 2001-12-31 | $692.00M | -13.93% |
| 2000-12-31 | $804.00M | -11.16% |
| 1999-12-31 | $905.00M | - |
Edwards Lifesciences generated $6.00B in revenue during NA 2023, up 11.56% compared to the previous quarter, and up 161.30% compared to the same period a year ago.
Edwards Lifesciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.39B | -13.28% |
| 2024-03-31 | $1.60B | 4.18% |
| 2023-12-31 | $1.53B | 3.59% |
| 2023-09-30 | $1.48B | -3.22% |
| 2023-06-30 | $1.53B | 4.84% |
| 2023-03-31 | $1.46B | 8.25% |
| 2022-12-31 | $1.35B | 2.22% |
| 2022-09-30 | $1.32B | -4.00% |
| 2022-06-30 | $1.37B | 2.44% |
| 2022-03-31 | $1.34B | 0.86% |
| 2021-12-31 | $1.33B | 1.49% |
| 2021-09-30 | $1.31B | -4.78% |
| 2021-06-30 | $1.38B | 13.10% |
| 2021-03-31 | $1.22B | 2.09% |
| 2020-12-31 | $1.19B | 4.45% |
| 2020-09-30 | $1.14B | 23.34% |
| 2020-06-30 | $925.00M | -18.05% |
| 2020-03-31 | $1.13B | -3.87% |
| 2019-12-31 | $1.17B | 7.32% |
| 2019-09-30 | $1.09B | 0.65% |
| 2019-06-30 | $1.09B | 9.46% |
| 2019-03-31 | $993.00M | 1.56% |
| 2018-12-31 | $977.70M | 7.84% |
| 2018-09-30 | $906.60M | -3.93% |
| 2018-06-30 | $943.70M | 5.46% |
| 2018-03-31 | $894.80M | 0.71% |
| 2017-12-31 | $888.50M | 8.16% |
| 2017-09-30 | $821.50M | -2.41% |
| 2017-06-30 | $841.80M | -4.72% |
| 2017-03-31 | $883.50M | 15.08% |
| 2016-12-31 | $767.70M | 3.83% |
| 2016-09-30 | $739.40M | -2.62% |
| 2016-06-30 | $759.30M | 8.89% |
| 2016-03-31 | $697.30M | 3.90% |
| 2015-12-31 | $671.10M | 9.03% |
| 2015-09-30 | $615.50M | -0.21% |
| 2015-06-30 | $616.80M | 4.49% |
| 2015-03-31 | $590.30M | -4.48% |
| 2014-12-31 | $618.00M | 1.75% |
| 2014-09-30 | $607.40M | 5.62% |
| 2014-06-30 | $575.10M | 10.09% |
| 2014-03-31 | $522.40M | -2.54% |
| 2013-12-31 | $536.00M | 8.15% |
| 2013-09-30 | $495.60M | -4.18% |
| 2013-06-30 | $517.20M | 4.13% |
| 2013-03-31 | $496.70M | -2.70% |
| 2012-12-31 | $510.50M | 13.98% |
| 2012-09-30 | $447.90M | -7.07% |
| 2012-06-30 | $482.00M | 4.97% |
| 2012-03-31 | $459.20M | 6.74% |
| 2011-12-31 | $430.20M | 4.24% |
| 2011-09-30 | $412.70M | -4.29% |
| 2011-06-30 | $431.20M | 6.60% |
| 2011-03-31 | $404.50M | 3.08% |
| 2010-12-31 | $392.40M | 12.47% |
| 2010-09-30 | $348.90M | -4.46% |
| 2010-06-30 | $365.20M | 7.25% |
| 2010-03-31 | $340.50M | -1.79% |
| 2009-12-31 | $346.70M | 6.45% |
| 2009-09-30 | $325.70M | -2.92% |
| 2009-06-30 | $335.50M | 7.02% |
| 2009-03-31 | $313.50M | 1.23% |
| 2008-12-31 | $309.70M | 2.01% |
| 2008-09-30 | $303.60M | -7.33% |
| 2008-06-30 | $327.60M | 10.38% |
| 2008-03-31 | $296.80M | - |
Edwards Lifesciences generated $1.39B in revenue during Q2 2024, up -13.28% compared to the previous quarter, and up 94.95% compared to the same period a year ago.
Edwards Lifesciences Revenue Breakdown
Edwards Lifesciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $3.88B | $3.52B | $3.42B | $2.86B | - |
| Surgical Heart Valve Therapy | $999.30M | $893.10M | $889.10M | $761.80M | $841.70M |
| Critical Care | $928.10M | $855.00M | $834.90M | $725.40M | $740.20M |
| Transcatheter Mitral And Tricuspid Therapies | $197.60M | $116.10M | $86.00M | $41.80M | $28.20M |
| Transcatheter Heart Valves | - | - | - | - | $2.74B |
Edwards Lifesciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Transcatheter Aortic Valve Replacement (64.61%), Surgical Heart Valve Therapy (16.64%), Critical Care (15.46%), and Transcatheter Mitral And Tricuspid Therapies (3.29%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Heart Valve Therapy | $264.30M | $266.10M | $248.20M | $246.60M | $256.30M | $248.20M | $224.10M | $219.70M | $228.50M | $220.80M | $221.30M | $217.40M | $237.40M | $213.00M | $204.20M | $203.30M | $160.90M | $193.40M | $205.10M | $204.10M |
| Transcatheter Heart Valves | $1.04B | $1.01B | $979.40M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Transcatheter Mitral And Tricuspid Therapies | $83.00M | $72.90M | $56.00M | $52.40M | $47.60M | $41.60M | $31.50M | $29.70M | $27.90M | $27.00M | $25.30M | $22.30M | $22.10M | $16.30M | $13.10M | $12.10M | $6.10M | $10.50M | $7.20M | $9.70M |
| Critical Care | - | $251.30M | $250.50M | $221.00M | $234.70M | $221.90M | $225.00M | $207.30M | $210.60M | $212.10M | $211.60M | $212.70M | $215.00M | $195.60M | $198.20M | $180.90M | $163.70M | $182.60M | $199.30M | $180.20M |
| Transcatheter Aortic Valve Replacement | - | - | $979.40M | $960.90M | $991.60M | $947.90M | $867.70M | $862.30M | $906.90M | $881.30M | $871.50M | $857.80M | $901.50M | $791.70M | $776.20M | $744.60M | $594.30M | $742.20M | $700.00M | - |
Edwards Lifesciences's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Transcatheter Heart Valves (74.94%), Surgical Heart Valve Therapy (19.07%), and Transcatheter Mitral And Tricuspid Therapies (5.99%).
Edwards Lifesciences Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| JAPAN | $452.40M | $473.60M | $528.90M | $460.10M | $444.70M |
| Rest of World | $709.20M | $601.40M | $550.20M | $435.80M | $429.40M |
| UNITED STATES | $3.51B | $3.13B | $2.96B | $2.52B | $2.53B |
| Europe | $1.33B | $1.17B | $1.19B | $973.60M | $941.20M |
Edwards Lifesciences's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (58.43%), Europe (22.22%), Rest of World (11.81%), and JAPAN (7.53%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rest of World | $146.10M | $178.90M | $182.80M | $180.30M | $180.80M | $165.30M | $150.90M | $158.00M | $147.40M | $145.10M | $141.90M | $140.00M | $138.70M | $129.60M | $125.30M | $111.20M | $97.30M | $102.00M | $114.40M | $110.70M |
| UNITED STATES | $816.80M | $940.70M | $894.40M | $869.90M | $895.30M | $849.10M | $795.50M | $786.80M | $800.80M | $749.50M | $739.50M | $753.20M | $795.70M | $674.70M | $671.20M | $662.00M | $516.20M | $667.40M | $697.20M | $647.80M |
| Europe | $335.60M | $367.80M | $344.90M | $322.30M | $336.20M | $331.10M | $290.80M | $270.10M | $302.80M | $311.10M | $309.40M | $291.10M | $309.80M | $280.00M | $265.80M | $253.80M | $204.70M | $249.30M | $242.20M | $222.60M |
| JAPAN | $87.40M | $110.80M | $112.00M | $108.40M | $117.90M | $114.10M | $111.10M | $104.10M | $122.90M | $135.50M | $138.90M | $125.90M | $131.80M | $132.30M | $129.40M | $113.90M | $106.80M | $110.00M | $120.30M | $112.90M |
Edwards Lifesciences's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (58.94%), Europe (24.22%), Rest of World (10.54%), and JAPAN (6.31%).
Edwards Lifesciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ABT | Abbott Laboratories | $40.11B | $10.38B |
| MDT | Medtronic | $32.36B | $7.92B |
| SYK | Stryker | $20.50B | $5.42B |
| EW | Edwards Lifesciences | $6.00B | $1.39B |
| ALGN | Align | $3.86B | $1.03B |
| DXCM | DexCom | $3.62B | $1.00B |
| ZBH | Zimmer Biomet | $1.94B | $1.89B |
| PODD | Insulet | $1.70B | $488.50M |
| TNDM | Tandem Diabetes Care | $747.72M | $331.03M |
EW Revenue FAQ
What is Edwards Lifesciences’s yearly revenue?
Edwards Lifesciences's yearly revenue for 2023 was $6B, representing an increase of 11.56% compared to 2022. The company's yearly revenue for 2022 was $5.38B, representing an increase of 2.86% compared to 2021. EW's yearly revenue for 2021 was $5.23B, representing an increase of 19.29% compared to 2020.
What is Edwards Lifesciences’s quarterly revenue?
Edwards Lifesciences's quarterly revenue for Q2 2024 was $1.39B, a -13.28% decrease from the previous quarter (Q1 2024), and a -9.43% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.6B, a 4.18% increase from the previous quarter (Q4 2023), and a 9.50% increase year-over-year (Q1 2023). EW's quarterly revenue for Q4 2023 was $1.53B, a 3.59% increase from the previous quarter (Q3 2023), and a 13.78% increase year-over-year (Q4 2022).
What is Edwards Lifesciences’s revenue growth rate?
Edwards Lifesciences's revenue growth rate for the last 3 years (2021-2023) was 14.76%, and for the last 5 years (2019-2023) was 38.10%.
What are Edwards Lifesciences’s revenue streams?
Edwards Lifesciences's revenue streams in c 23 are Transcatheter Aortic Valve Replacement, Surgical Heart Valve Therapy, Critical Care, and Transcatheter Mitral And Tricuspid Therapies. Transcatheter Aortic Valve Replacement generated $3.88B in revenue, accounting 64.61% of the company's total revenue, up 10.28% year-over-year. Surgical Heart Valve Therapy generated $999.3M in revenue, accounting 16.64% of the company's total revenue, up 11.89% year-over-year. Critical Care generated $928.1M in revenue, accounting 15.46% of the company's total revenue, up 8.55% year-over-year. Transcatheter Mitral And Tricuspid Therapies generated $197.6M in revenue, accounting 3.29% of the company's total revenue, up 70.20% year-over-year.
What is Edwards Lifesciences’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Edwards Lifesciences was Transcatheter Aortic Valve Replacement. This segment made a revenue of $3.88B, representing 64.61% of the company's total revenue.